Table VI:

Association of CSF candidate biomarker concentrations of neonates with NE and clinical encephalopathy

	Univariate Analysis			Adjusted Logistic Regression*
	Mild (Sarnat 0–1) Median (IQR)	Moderate-to-Severe (Sarnat 2–3) Median (IQR)	p	Coefficient (95% CI)	p
GFAP	322 (220, 395)	247 (156, 415)	0.54	−0.118 (−0.953–0.716)	0.78
NRGN	7 (7, 24)	7 (7, 7)	0.50	−0.783 (−2.439–0.873)	0.35
BDNF	30.3 (30.3, 30.3)	30.3 (30.3, 30.3)	0.57	-
IL-6	4.0 (3.1, 142.6)	3.8 (0.2, 36.2)	0.46	−0.135 (−0.580–0.311)	0.55
IL-8	369.9 (160.4, 501.2)	203.5 (78.4, 606.1)	0.76	−0.122 (−0.777–0.532)	0.71
IL-10	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	0.70	-
VEGF	4.5 (2.0, 6.6)	4.9 (3.3, 9.6)	0.46	0.603 (−0.784–1.990)	0.39
Tau	3223.9 (56.6, 2.8e+04)	2626.1 (56.6, 6721.5)	0.80	−0.016 (−0.446–0.415)	0.94

NE = neonatal encephalopathy, CSF = cerebrospinal fluid. Univariate analyses used the Mann-Whitney U test for comparisons of non-parametric data. Candidate biomarker units are pg/mL. Duplex (GFAP and NRGN): Mild n=4, Moderate-to-Severe n=26; Multiplex (BDNF, IL-6, IL-8, IL-10, VEGF): Mild n=4, Moderate-to-Severe n=26; Tau: Mild n=4, Moderate-to-Severe n=23.

^*Adjusted for gestational age and sex, the natural log of candidate biomarker concentrations were used in adjusted analyses.